Consensus on the management of malignant melanoma of the skin in the Netherlands

被引:22
作者
Kroon, BBR
Bergman, W
Coebergh, JWW
Ruiter, DJ
机构
[1] Netherlands Canc Inst, Dept Surg, Antoni Van Leeuwenhoek Ziekenhuis, NL-1066 CX Amsterdam, Netherlands
[2] Leiden Univ Hosp, Dept Dermatol, NL-2333 AA Leiden, Netherlands
[3] Erasmus Univ, Dept Epidemiol & Biostat, NL-3000 DR Rotterdam, Netherlands
[4] Univ Nijmegen Hosp, Inst Pathol, NL-6500 HB Nijmegen, Netherlands
关键词
consensus on management; malignant melanoma;
D O I
10.1097/00008390-199906000-00001
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In 1996 the Dutch Melanoma Working Party, in co-operation with the National Organization for Quality Assurance in Hospitals in the Netherlands and the Dutch Association of Comprehensive Cancer Centres, organized the third consensus conference on the management of melanoma of the skin. The following guidelines were approved. The recommended margin for diagnostic excision is 2 mm of macroscopically normal skin around the lesion; the margins for therapeutic excision are 1 cm of normal skin for a Breslow thickness of less than or equal to 2 mm and 2 cm for a Breslow thickness of > 2 and less than or equal to 4 mm. A margin of at least 2 cm also appears to be justified for thicker melanomas. Elective lymph node dissection is not recommended. Sentinel node biopsy appears to be a promising method to detect occult metastases in the regional lymph nodes. If regional lymph node metastases are present, therapeutic regional lymph node dissection must be conducted. Isolated regional perfusion is indicated for inoperable tumour growth in an extremity. Radiotherapy can be applied curatively (for example, if surgery is not possible), palliatively (if desired in combination with hyperthermia) or postoperatively (if non-radical resection is suspected). Adjuvant systemic therapy for melanoma patients is still experimental. Atypical (dysplastic) naevi and congenital naevi are major risk factors for melanoma. No consensus has been reached about the prophylactic excision of all congenital naevi. A follow-up period of 5 years is sufficient for patients with a melanoma of less than or equal to 1.5 mm Breslow thickness (provided there are no histological signs of regression) and of 10 years when the Breslow thickness is > 1.5 mm. The patient should be actively involved in the follow-up (inspection, palpation). Regular routine blood tests, radiological examination and ultrasound scanning are not considered to be worthwhile. There is no evidence that the growth of micro-metastases is stimulated by hormonal changes during pregnancy or contraceptive pill use. Excessive exposure to ultraviolet radiation should be discouraged. Regular population screening for melanoma is not considered to be worthwhile, owing to the relatively low frequency and the predominantly favourable stage at the time of diagnosis, particularly in young people. (C) 1999 Lippincott Williams & Wilkins.
引用
收藏
页码:207 / 212
页数:6
相关论文
共 26 条
[1]   Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger [J].
Balch, CM ;
Soong, SJ ;
Bartolucci, AA ;
Urist, MM ;
Karakousis, CP ;
Smith, TJ ;
Temple, WJ ;
Ross, MI ;
Jewell, WR ;
Mihm, MC ;
Barnhill, RL ;
Wanebo, HJ .
ANNALS OF SURGERY, 1996, 224 (03) :255-263
[2]   EFFICACY OF 2-CM SURGICAL MARGINS FOR INTERMEDIATE-THICKNESS MELANOMAS (1 TO 4 MM) - RESULTS OF A MULTIINSTITUTIONAL RANDOMIZED SURGICAL TRIAL [J].
BALCH, CM ;
URIST, MM ;
KARAKOUSIS, CP ;
SMITH, TJ ;
TEMPLE, WJ ;
DRZEWIECKI, K ;
JEWELL, WR ;
BARTOLUCCI, AA ;
MIHM, MC ;
BARNHILL, R ;
WANEBO, HJ .
ANNALS OF SURGERY, 1993, 218 (03) :262-269
[3]   A MULTIFACTORIAL ANALYSIS OF MELANOMA .3. PROGNOSTIC FACTORS IN MELANOMA PATIENTS WITH LYMPH-NODE METASTASES (STAGE-II) [J].
BALCH, CM ;
SOONG, SJ ;
MURAD, TM ;
INGALLS, AL ;
MADDOX, WA .
ANNALS OF SURGERY, 1981, 193 (03) :377-388
[4]  
COEBERGH JWW, 1995, CANC INCIDENCE SURVI, P48
[5]   Neonatal curettage of giant congenital melanocytic nevi [J].
DeRaeve, LE ;
DeConinck, AL ;
Dierichx, PR ;
Roseeuw, DI .
ARCHIVES OF DERMATOLOGY, 1996, 132 (01) :20-22
[6]  
ELDER DE, 1991, ATLAS TUMOR PATHOLOG
[7]   LYMPH-NODE METASTASIS FROM MELANOMA WITH AN UNKNOWN PRIMARY SITE [J].
JONK, A ;
KROON, BBR ;
RUMKE, P ;
MOOI, WJ ;
HART, AAM ;
VANDONGEN, JA .
BRITISH JOURNAL OF SURGERY, 1990, 77 (06) :665-668
[8]   Localizing the sentinel node in cutaneous melanoma: Gamma probe detection versus blue dye [J].
Kapteijn, BAE ;
Nieweg, OE ;
Liem, IH ;
Mooi, WJ ;
Balm, AJM ;
Muller, SH ;
Peterse, JL ;
Olmos, RAV ;
Hoefnagel, CA ;
Kroon, BBR .
ANNALS OF SURGICAL ONCOLOGY, 1997, 4 (02) :156-160
[9]   Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group trial EST 1684 [J].
Kirkwood, JM ;
Strawderman, MH ;
Ernstoff, MS ;
Smith, TJ ;
Borden, EC ;
Blum, RH .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (01) :7-17
[10]  
KOOPS HS, 1997, MELANOMA RES S1, V7, pS34